11. (Amended) A method of vaccinating a human or animal against disease comprising [the step of] administering to the human or animal a composition comprising an immunologically effective amount of [an admixture of a colloidal metal and] a biologically-active factor admixed with or bound to a colloidal metal such that an effective amount of the biologically-active factor is released from the composition *in vivo*

.

12. (Amended) The method of Claim 11, wherein the [toxic] biologically-active factor is selected from the group consisting of interleukin-2 ("IL-2"), lipid A, phospholipase A2, endotoxins, staphylococcal enterotoxin B, Type I Interferon, Type II Interferon, tumor necrosis factor, IL-1, IL-6, IL-8, IL-4, Transforming Growth Factor-B, Lymphotoxin, IL-5, Migration Inhibition Factor, IL-3, Granulocyte-Macrophage Colony-Stimulating Factor ("CSF"), Monocyte-Macrophage CSF, Granulocyte CSF, IL-7, IL-l0, IL-11, IL-12, IL-13, vascular epithelial growth factor ("VEGF"), Angiogenin, transforming growth factor alpha ("TGF-α"), transforming growth factor beta ("TGF-β"), heat shock proteins, carbohydrate moieties of blood groups, Rh factors, hormones, receptors, DNA, glucose, antibodies, and fibroblast growth factor.

15. (Amended) A method of treating a human or animal with a cancer or immune disease comprising [the step of] administering to the human or animal with the cancer or immune disease a therapeutically effective amount of a composition comprising [an admixture of a colloidal metal and a toxic] a biologically-active factor admixed with or bound to a colloidal metal.

16. (Amended) The method of Claim 15, wherein the [toxic] biologically-active factor is selected from the group consisting of Interleukin-2 ("IL-2"), lipid A, phospholipase A2, endotoxins, staphylococcal enterotoxin B, Type I Interferon, Type II Interferon, tumor necrosis factor, IL-1, IL-6, IL-8, IL-4, Transforming Growth Factor-B, Lymphotoxin, IL-5, Migration Inhibition Factor, IL- 3, Granulocyte-Macrophage Colony-Stimulating Factor ("CSF"), Monocyte-Macrophage CSF, Granulocyte CSF, IL-7, IL-l0, IL-11, IL-12, IL-13, vascular epithelial growth factor ("VEGF"), Angiogenin, transforming growth factor alpha ("TGF-α"), transforming growth factor beta ("TGF-β"),

heat shock proteins, carbohydrate moieties of blood groups, Rh factors, hormones, receptors, DNA, glucose, antibodies, and fibroblast growth factor.

19. (Amended) A method for the delivery of [one or] more than one biologically-active factor[s] comprising administering to a human or animal a composition comprising [one or] more than one biologically-active factor[s] admixed with or bound to a colloidal metal such that one or more of the biologically-active factors are released from the composition *in vivo*.

21. (Amended) A method for the targeted delivery of one or more biologically-active factors, comprising administering to a human or animal a composition comprising one or more biologically-active factors admixed with or bound to colloidal metal wherein at least one of the biologically-active factors is a target molecule capable of binding a receptor on a cell membrane and wherein at least one of the biologically-active factors is released from the composition *in vivo*.

24. (Twice Amended) A method of treating a human or animal with cancer or an immune disease comprising administering to [a] the human or animal a composition comprising [an admixture of a colloidal metal and] one or more biologically-active factors admixed with or bound to a colloidal metal, wherein at least one of the biologically-active factors is a target molecule capable of binding a [high affinity] receptor on a cell membrane.

In Claim 26, line 1: change "Claim 30" to -- Claim 24--.

27. (New) The composition of Claim 1, further comprising additional biologically-active factors admixed with or bound to the colloidal metal.

28. (New) The composition of Claim 8, further comprising additional biologically-active factors admixed with or bound to the colloidal metal.

29. (New) The method of Claim 9, wherein the composition further comprises additional biologically-active factors admixed with or bound to the colloidal metal.